Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00793182 · ClinicalTrials.gov registry record · Phase 4
Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography
A Phase 4 study, sponsored by Guerbet.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT00793182 is a Phase 4 study that was terminated before completion, run by Guerbet. The registered enrollment target is 6 participants.
The verdict
NCT00793182, a Phase 4 study, was terminated before completion, sponsored by Guerbet.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the contrast-induced nephropathy (CIN) rate in subjects randomized to receive either Ioversol or Iodixanol for contrast-enhanced computed tomography.
Interventions
- DRUG Ioversol 320 mgI/mL
- DRUG Iodixanol 320 mgI/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00793182
The ClinicalTrials.gov registry entry for NCT00793182 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Guerbet, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ioversol 320 mgI/mL is the first listed.
NCT00793182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00793182 about?
NCT00793182 is a clinical study titled "Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography". The purpose of this study is to evaluate the contrast-induced nephropathy (CIN) rate in subjects randomized to receive either Ioversol or Iodixanol for contrast-enhanced computed tomography.
What is the current status of trial NCT00793182?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2009-01. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00793182?
The interventions under investigation include: Ioversol 320 mgI/mL (DRUG), Iodixanol 320 mgI/mL (DRUG).
Who is sponsoring clinical trial NCT00793182?
This trial is sponsored by Guerbet, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.